This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Bauman JE , Cohen E , Ferris RL , Adelstein DJ , Brizel DM , Ridge JA , O'Sullivan B , Burtness BA , Butterfield LH , Carson WE , Disis ML , Fox BA , Gajewski TF , Gillison ML , Hodge JW , Le QT , Raben D , Strome SE , Lynn J , Malik S
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
Cancer. 2017 Apr 01;123(7) :1259-1271
PMID: 27906454 PMCID: PMC5705038 URL: https://www.ncbi.nlm.nih.gov/pubmed/27906454
AbstractRecent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents are being rapidly adopted by the oncologic community and hold considerable promise. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with previously untreated, human papillomavirus-initiated oropharyngeal cancers; those with previously untreated, human papillomavirus-negative HNSCC; and those with recurrent/metastatic HNSCC. In addition, a separate committee was formed to develop integrative biomarkers for the clinical trials. The meeting started with an overview of key immune components and principles related to HNSCC, including immunosurveillance and immune escape. Four clinical trial concepts were developed at the meeting integrating different immunotherapies with existing standards of care. These designs were presented for implementation by the head and neck committees of the National Cancer Institute-funded National Clinical Trials Network. This article summarizes the proceedings of this Clinical Trials Planning Meeting, the purpose of which was to facilitate the rigorous development and design of randomized phase 2 and 3 immunotherapeutic trials in patients with HNSCC. Although reviews usually are published immediately after the meeting is held, this report is unique because there are now tangible clinical trial designs that have been funded and put into practice and the studies are being activated to accrual. Cancer 2017;123:1259-1271. (c) 2016 American Cancer Society.
NotesBauman, Julie E Cohen, Ezra Ferris, Robert L Adelstein, David J Brizel, David M Ridge, John A O'Sullivan, Brian Burtness, Barbara A Butterfield, Lisa H Carson, William E Disis, Mary L Fox, Bernard A Gajewski, Thomas F Gillison, Maura L Hodge, James W Le, Quynh-Thu Raben, David Strome, Scott E Lynn, Jean Malik, Shakun eng Congresses 2016/12/03 06:00 Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.